PIK3C3 and Insulin resistance: In this study, we report that partial in vivo inactivation of the Vps34 isoform of PI3K enhances insulin sensitivity and glucose tolerance, identifying this kinase as a new drug target for the treatment of insulin resistance including Type-2 diabetes, a condition in which the unmet therapeutic need remains substantial.